OverviewSuggest Edit

Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
TypePublic
Founded2012
HQWinter Park, US
Websiteimmunetherapeutics.com

Latest Updates

Employees (est.) (Feb 2019)4(-60%)
Revenue (FY, 2018)$113.5 K(+3178%)
Share Price (May 2020)$0 (-8%)

Key People/Management at Immune Therapeutics

Michael K. Handley

Michael K. Handley

CEO
Peter Aronstram

Peter Aronstram

CFO
Fengpin Shan

Fengpin Shan

CSO
Show more

Immune Therapeutics Office Locations

Immune Therapeutics has offices in Winter Park and Orlando
Winter Park, US (HQ)
2431 Aloma Ave #124
Orlando, US
37 N Orange Ave #607
Show all (2)

Immune Therapeutics Financials and Metrics

Immune Therapeutics Revenue

Immune Therapeutics's revenue was reported to be $113.50 k in FY, 2018
USD

Net income (Q3, 2019)

(941.5k)

EBIT (Q3, 2019)

(389.2k)

Market capitalization (21-May-2020)

6.3m

Closing stock price (21-May-2020)

0.0

Cash (30-Sept-2019)

6.5k

EV

11.9m
Immune Therapeutics's current market capitalization is $6.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

16.2k3.5k113.5k

Revenue growth, %

(79%)

Cost of goods sold

47.7k

Gross profit

65.8k
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

2.1k5.6k5.0k3.5k65.0k

Cost of goods sold

33.2k

Gross profit

31.8k

Gross profit Margin, %

49%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

406.6k192.0k23.1k74.4k14.7k5.9k

Accounts Receivable

16.2k

Prepaid Expenses

215.9k30.0k

Inventories

178.1k82.8k
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

176.2k231.5k207.7k233.7k58.7k58.6k30.9k22.4k153.9k132.8k64.3k22.2k98.1k45.0k22.6k30.4k5.9k5.7k21.4k6.5k

Accounts Receivable

2.1k7.7k12.7k19.7k2.7k

Prepaid Expenses

130.0k30.9k45.0k42.5k35.0k49.7k30.0k30.0k45.4k1.6k11.3k

Inventories

214.3k158.6k158.6k158.6k82.8k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)(7.9m)(8.6m)

Depreciation and Amortization

2.9m2.9m594.8k1.6k826.01.7k

Inventories

(178.1k)95.3k

Accounts Payable

553.2k1.8m900.5k541.0k919.1k341.6k
USDY, 2019

EV/EBIT

-30.5 x

EV/CFO

19.9 k x
Show all financial metrics

Immune Therapeutics Online and Social Media Presence

Embed Graph

Immune Therapeutics News and Updates

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

ORLANDO, Fla., Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy and a…

Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors

ORLANDO, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and infla…

Immune Therapeutics, Inc. Provides Shareholder Update on 14A

ORLANDO, Fla., May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, ca…

Immune Therapeutics welcomes Kevin Phelps to Board of Directors

ORLANDO, Fla., Jan. 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune Therapeutics”, “IMUN” or the “Company”), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory…

Immune Therapeutics Welcomes Amb. Jack Brewer to the Board of Directors

ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and infla…

Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Board

ORLANDO, Fla., Aug. 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune Therapeutics", "IMUN" or the "Company"), a late stage clinical biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory…

Immune Therapeutics Blogs

Immune Therapeutics Welcomes AMB Jack Brewer to the Board of Directors

ORLANDO, Fla., Sept. 06, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflamm…

Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry

ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE - - Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today announced that the…

The Plan of Four-Dimensional Regulation (4D Plan) For Cancer Patients: First Systematic Plan For Cancer Patients In The World

by Fengping Shan(https://sciencetrends.com/author/staff/) Cancer is still a global issue. Surgery, chemotherapy, radiotherapy, and present immune therapy do prolong the lives of cancer patients, but these cannot correct a disordered immune system, a result of cancer. Free radicals are often hazardou…

International Immunopharmacology: Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-…

Immune Therapeutics Adds Former United States Assistant Surgeon General Dr. Roscoe Moore to Board of Directors

ORLANDO, Fla., Aug. 07, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--Immune Therapeutics, Inc. (OTC:IMUN) (IMUN) ("Immune" "IMUN" or the "Company"), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammat…

Immune Therapeutics Inc Announces Publication of Peer Reviewed Scientific Paper Describing Low-Dose Naltrexone (LDN): A Promising Treatment in Immune-Related Diseases and Cancer Therapies

ORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cance…
Show more

Immune Therapeutics Frequently Asked Questions

  • When was Immune Therapeutics founded?

    Immune Therapeutics was founded in 2012.

  • Who are Immune Therapeutics key executives?

    Immune Therapeutics's key executives are Michael K. Handley, Peter Aronstram and Fengpin Shan.

  • How many employees does Immune Therapeutics have?

    Immune Therapeutics has 4 employees.

  • What is Immune Therapeutics revenue?

    Latest Immune Therapeutics annual revenue is $113.5 k.

  • What is Immune Therapeutics revenue per employee?

    Latest Immune Therapeutics revenue per employee is $28.4 k.

  • Who are Immune Therapeutics competitors?

    Competitors of Immune Therapeutics include Cue Biopharma, ANI Pharmaceuticals and scPharmaceuticals.

  • Where is Immune Therapeutics headquarters?

    Immune Therapeutics headquarters is located at 2431 Aloma Ave #124, Winter Park.

  • Where are Immune Therapeutics offices?

    Immune Therapeutics has offices in Winter Park and Orlando.

  • How many offices does Immune Therapeutics have?

    Immune Therapeutics has 2 offices.